menu
    • menu
    [{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SC0062","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BC3195","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BC3448","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"BC3402","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ AstraZeneca"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SC0062","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BC2027","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BC3402","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"BioCity Biopharma \/ AstraZeneca"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SC0062","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SC0062","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioCity Biopharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by BioCity Biopharma

    Menu

    BioCity Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC0062

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCity’s SC0062 Receives Breakthrough Therapy For IgA Nephropathy

                            Details : SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of IgA Nephropathy.

                            Brand Name : SC0062

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 26, 2024

                            Lead Product(s) : SC0062

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC0062

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCity’s SC0062 Meets Primary Endpoint in IgA Nephropathy in 2-SUCCEED Phase 2 Trial

                            Details : SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of IgA Nephropathy.

                            Brand Name : SC0062

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 08, 2024

                            Lead Product(s) : SC0062

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC2027

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCity Announces FDA Clearance of IND Application for ADC Targeting Glypican 3

                            Details : BC2027 is a first-in-class antibody drug conjugate which targets Glypican 3 (GPC3), a proteoglycan found in the outer membrane of cancer cells. It is being evaluated for the treatment of liver cancer.

                            Brand Name : BC2027

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 09, 2024

                            Lead Product(s) : BC2027

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC0062

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCity Completes Enrollment in Phase II Trial of SC0062 for IgA Nephropathy

                            Details : SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of IgA Nephropathy.

                            Brand Name : SC0062

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 26, 2024

                            Lead Product(s) : SC0062

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC3402,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCity Announces the First Patient Dosed with its Anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the T...

                            Details : BioCity evaluating Phase I/II clinical trial studies of its BC3402 anti-TIM-3 monoclonal antibody in combination with Imfinzi (durvalumab) or the treatment of advanced hepatocellular carcinoma in China.

                            Brand Name : BC3402

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : BC3402,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC3402,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a Monoclonal Antibody Targeting Anti-TIM-3, ...

                            Details : The collaboration aims to evaluate BioCity's BC3402, a mAb targeting the T cell immunoglobulin and mucin domain-containing protein 3, in combination with AstraZeneca's anti-PD-L1 mAb IMFINZI (durvalumab) for the treatment of advanced hepatocellular carci...

                            Brand Name : BC3402

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 27, 2023

                            Lead Product(s) : BC3402,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC3448

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCity Announces FDA Clearance of Investigational New Drug Application for its First-in-Class CD3/EGFR Bispec...

                            Details : BC3448 is a CD3-based BsAb that recruits T cells to tumors cells with high EGFR expression resulting in T cell-driven tumor cell killing and is being developed in solid tumors with high EGFR expression, including NSCLC, HNSCC, mCRC, and ESC.

                            Brand Name : BC3448

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 07, 2023

                            Lead Product(s) : BC3448

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC3195

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCity Announces the First Patient Dosed with Its First-In-Class CDH3-targeting ADC BC3195 in a Phase 1 Trial

                            Details : BC3195 is a novel ADC targeting CDH3/P-cadherin, a calcium-dependent cell-cell adhesion glycoprotein highly expressed in a variety of malignancies, including lung, breast, gastric, ovarian, colorectal, and pancreatic cancers.

                            Brand Name : BC3195

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 19, 2023

                            Lead Product(s) : BC3195

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed

                            BioCity Biopharma

                            China arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC0062

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Ki...

                            Details : SC0062 is designed with high selectivity for ETA receptors antagonists, which is investigated for the treatment of chronic kidney disease with albuminuria.

                            Brand Name : SC0062

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 21, 2023

                            Lead Product(s) : SC0062

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth